SecBot SecBot
144 ·Filed Oct 29, 2026

ANGO

ANGIODYNAMICS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 6h ago SEC0001950047-26-010465
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale notice with no unusual size or timing relative to company events. Monitor for actual Form 4 filings to confirm execution, but no material market impact is expected from this filing alone.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$11.99
T+0 close · Oct 29, 2026 · via day close
Latest settled
−1.92%
T+1 · $11.76 · next T+5 due 14h ago
vs SPY
−1.44%
α at T+1
Latest observation
−2.17%
T+2 · FF3 residual α
  1. T+0 · Oct 29 $11.99entry
  2. T+1 · 7d ago −1.92%α −1.44% · $11.76
  3. T+5 · due 14h ago Pending
  4. T+5 · todayOpen
  5. T+20 · in 21d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Stephen Trowbridge, an officer of AngioDynamics, filed a Form 144 notice of intent to sell 23,615 shares of common stock, with an approximate market value of $289,722 based on the filing date. The shares were acquired through restricted stock vesting and employee stock purchase plan purchases over a multi-year period. The proposed sale represents a modest portion of the officer's total holdings and is routine in nature.

Key Facts

  • Officer Stephen Trowbridge filed Form 144 to sell 23,615 shares of AngioDynamics common stock.
  • Estimated sale value is approximately $289,722 based on the filing date.
  • Shares were acquired via restricted stock vesting (08/03/2015 through 07/21/2025) and Employee Stock Purchase Plan (08/31/2015 through 08/31/2025).
  • The sale is proposed to occur on or after 10/29/2026 on the Nasdaq exchange.
  • The filing is an advance notice of intent to sell, not a completed transaction.

Financial Impact

23,615 shares at ~$289,722 total value, representing approximately 0.06% of AngioDynamics' $516M market cap.

dilution

Risk Factors

  • Form 144 is only an intent to sell; the transaction may not be executed.
  • No additional context on the officer's total holdings or recent trading patterns is available in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010465
Document: 0001950047-26-010465-index.html0001950047-26-010465
Document: 0001950047-26-010465.txt0001950047-26-010465
8 reports for ANGO
Performance horizon
100% Hit rate @ T+20 3 of 3 bullish or bearish reports Went positive at some point 3 of 3 best @ T+60▲ +26.19%Apr 2, 2026
Filters
Rows
Reports for ANGO, sortable and filterable
TypeNow
Nov 4, 2026
1d ago
3
NEUTRAL ★ 2/10
$12.14awaiting T+20awaiting T+20$12.25 (+0.91%)
Oct 29, 2026
7d ago
144
NEUTRAL ★ 2/10
$11.99awaiting T+20awaiting T+20$12.25 (+2.17%)
Oct 8, 2026
28d ago
DEFA14A
NEUTRAL ★ 4/10
$11.23 $11.81▲ +5.16%▲ +10.45%$12.25 (+9.08%)
Oct 8, 2026
28d ago
DEF 14A
NEUTRAL ★ 4/10
$11.23 $11.81▲ +5.16%▲ +10.45%$12.25 (+9.08%)
Oct 8, 2026
28d ago
8-K
BULLISH ★ 6/10
$11.23 $11.81▲ +5.16%▲ +10.45%$12.25 (+9.08%)
Oct 8, 2026
28d ago
8-K
NEUTRAL ★ 4/10
$11.23 $11.81▲ +5.16%▲ +10.45%$12.25 (+9.08%)
Jul 14, 2026
16w ago
8-K
BULLISH ★ 7/10
$13.00 $15.75▲ +21.15%▲ +18.66%$12.25 (−5.77%)
Apr 2, 2026
31w ago
8-K
BULLISH ★ 8/10
$10.31 $10.94▲ +6.11%▼ −3.77%$12.25 (+18.82%)
Showing 8 of 8

US Market Status

Market Closed · Opens Mon (60h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 29, 2026